Drug intelligence / Profile preview

igf2bp2 siRNA

Development stage
Preclinical
Lead developer
Osaka University
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01

Overview

IGF2BP2 siRNA is a small interfering RNA designed to silence the expression of Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2). In the context of endometrial cancer (EC), IGF2BP2 has been identified as a key driver of cell proliferation and tumor growth, particularly in refractory cases. By targeting IGF2BP2 mRNA for degradation, this siRNA inhibits the activation of the NF-kB signaling pathway, thereby suppressing oncogenic processes. Research conducted at Osaka University has demonstrated that IGF2BP2 knockdown significantly reduces tumor growth in both in vitro and in vivo models, suggesting its potential as a therapeutic strategy for treatment-resistant endometrial cancer.

Other names
IGF2BP2 small interfering RNAIGF-2BP2 small interfering RNAIGF 2BP2 small interfering RNAInsulin-like growth factor 2 mRNA-binding protein 2 siRNA
02

Targets

IGF2BP2AGO2 (Argonaute RISC catalytic component 2)

Beyond the preview

Go deeper on igf2bp2 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on igf2bp2 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call